Literature DB >> 21767180

Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours.

Jørgen B B Petersen1, Yasmin Lassen, Anders T Hansen, Ludvig P Muren, Cai Grau, Morten Høyer.   

Abstract

BACKGROUND: Stereotactic body radiotherapy (SBRT) is often the preferred treatment for the advanced liver tumours which owing to tumour distribution, size and multi-focality are out of range of surgical resection or radiofrequency ablation. However, only a minority of patients with liver tumours may be candidates for conventional SBRT because of the limited radiation tolerance of normal liver, intestine and other normal tissues. Due to the favourable depth-dose characteristics of protons, intensity-modulated proton therapy (IMPT) may be a superior alternative to photon-based SBRT. The purpose of this treatment planning study was therefore to investigate the potential sparing of normal liver by IMPT compared to photon-based intensity-modulated radiotherapy (IMRT) for solitary liver tumours.
MATERIAL AND METHODS: Ten patients with solitary liver metastasis treated at our institution with multi-field SBRT were retrospectively re-planned with IMRT and proton pencil beam scanning techniques. For the proton plans, two to three coplanar fields were used in contrast to five to six coplanar and non-coplanar photon fields. The same planning objectives were used for both techniques. A risk adapted dose prescription to the PTV surface of 12.5-16.75 Gy × 3 was used.
RESULTS: The spared liver volume for IMPT was higher compared to IMRT in all 10 patients. At the highest prescription dose level, the median liver volume receiving less than 15 Gy was 1411 cm(3) for IMPT and 955 cm(3) for IMRT (p < 0.005); also the mean liver dose was lower with IMPT compared to IMRT (median 9.1 Gy vs. 20.0 Gy; p < 0.005). All IMPT and IMRT plans met the V(D < 15 Gy) > 700 cm(3) constraint. For the D(mean) ≤ 15 Gy constraint, nine of 10 cases could be treated at the highest dose level using IMPT whereas with IMRT, only two cases met this constraint at the highest dose level and six at the lowest dose level.
CONCLUSION: A considerable sparing of normal liver tissue can be obtained using proton-based SBRT for solitary liver tumours.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767180     DOI: 10.3109/0284186X.2011.590526

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  15 in total

Review 1.  Proton beam therapy for gastrointestinal cancers: past, present, and future.

Authors:  Shahed N Badiyan; Christopher L Hallemeier; Steven H Lin; Matthew D Hall; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2018-10

2.  Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Authors:  Awalpreet S Chadha; Jillian R Gunther; Cheng-En Hsieh; Maureen Aliru; Lakshmi S Mahadevan; Bhanu P Venkatesulu; Christopher H Crane; Prajnan Das; Joseph M Herman; Eugene J Koay; Cullen Taniguchi; Emma B Holliday; Bruce D Minsky; Yelin Suh; Peter Park; Gabriel Sawakuchi; Sam Beddar; Bruno C Odisio; Sanjay Gupta; Evelyne Loyer; Harmeet Kaur; Kanwal Raghav; Milind M Javle; Ahmed O Kaseb; Sunil Krishnan
Journal:  Radiother Oncol       Date:  2019-01-16       Impact factor: 6.280

3.  Proton therapy for hepatocellular carcinoma.

Authors:  Ted C Ling; Joseph I Kang; David A Bush; Jerry D Slater; Gary Y Yang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

4.  Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions.

Authors:  Alex R Coffman; Daniel C Sufficool; Joseph I Kang; Chung-Tsen Hsueh; Sasha Swenson; Patrick Q McGee; Gayathri Nagaraj; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang
Journal:  J Gastrointest Oncol       Date:  2021-08

5.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

Review 6.  Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.

Authors:  Nitin Ohri; Laura A Dawson; Sunil Krishnan; Jinsil Seong; Jason C Cheng; Shiv K Sarin; Milan Kinkhabwala; Mansoor M Ahmed; Bhadrasain Vikram; C Norman Coleman; Chandan Guha
Journal:  J Natl Cancer Inst       Date:  2016-07-04       Impact factor: 13.506

7.  Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma.

Authors:  Dong Wook Kim; Kwangzoo Chung; Weon Kuu Chung; Sun Hyun Bae; Dong Oh Shin; Seongeon Hong; Sung Ho Park; Sung-Yong Park; Chae-Seon Hong; Young Kyung Lim; Dongho Shin; Se Byeong Lee; Hyun-ho Lee; Jiwon Sung; Myonggeun Yoon
Journal:  Radiat Oncol       Date:  2014-05-08       Impact factor: 3.481

8.  Dosimetric Comparison of Plans for Photon- or Proton-Beam Based Radiosurgery of Liver Metastases.

Authors:  Gracinda Mondlane; Michael Gubanski; Pehr A Lind; Thomas Henry; Ana Ureba; Albert Siegbahn
Journal:  Int J Part Ther       Date:  2016-12-30

9.  Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).

Authors:  Christos Dervenis; Evaghelos Xynos; George Sotiropoulos; Nikolaos Gouvas; Ioannis Boukovinas; Christos Agalianos; Nikolaos Androulakis; Athanasios Athanasiadis; Christos Christodoulou; Evangelia Chrysou; Christos Emmanouilidis; Panagiotis Georgiou; Niki Karachaliou; Ourania Katopodi; Panteleimon Kountourakis; Ioannis Kyriazanos; Thomas Makatsoris; Pavlos Papakostas; Demetris Papamichael; George Pechlivanides; Georgios Pentheroudakis; Ioannis Pilpilidis; Joseph Sgouros; Paris Tekkis; Charina Triantopoulou; Maria Tzardi; Vassilis Vassiliou; Louiza Vini; Spyridon Xynogalos; Nikolaos Ziras; John Souglakos
Journal:  Ann Gastroenterol       Date:  2016-06-03

10.  What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy.

Authors:  Chie Toramatsu; Norio Katoh; Shinichi Shimizu; Hideaki Nihongi; Taeko Matsuura; Seishin Takao; Naoki Miyamoto; Ryusuke Suzuki; Kenneth Sutherland; Rumiko Kinoshita; Rikiya Onimaru; Masayori Ishikawa; Kikuo Umegaki; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2013-03-05       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.